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Bioavailability of Ruminally or Abomasally Infused L-carnitine in Holstein Heifers
Abstract
This study evaluated the relative bioavailability of carnitine delivered by different methods in dairy cattle.
Four Holstein heifers were used in a split-plot design to compare ruminally or abomasally infused Lcarnitine. The study included 2 main-plot periods, with infusion routes allocated in a crossover design.
Within main-plot periods, each of 3 subplot periods consisted of 4-d infusions separated with 4-d rest
periods. Subplot treatments were infusion of 1, 3, and 6 g L-carnitine daily. Doses were increased within a
period to minimize carryover. Treatments were delivered in two 10-h infusions daily. Blood was collected
before the start of infusions and on day 4 of each infusion to obtain baseline and treatment carnitine
concentrations. There was a dose × route interaction (P < 0.05) and route effect (P < 0.01) for increases in
plasma carnitine above baseline, with increases above baseline being greater across all dose levels when
infused abomasally compared to ruminally. Results demonstrated superior bioavailability of carnitine
when ruminal exposure was physically bypassed.
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Bioavailability of Ruminally or Abomasally
Infused L-carnitine in Holstein Heifers
K. Olagaray, C. Armendariz, A. Bellamine,1 S. Jacobs,1 E. Titgemeyer,
and B.J. Bradford

Summary

This study evaluated the relative bioavailability of carnitine delivered by different methods in dairy cattle. Four Holstein heifers were used in a split-plot design to compare
ruminally or abomasally infused L-carnitine. The study included 2 main-plot periods,
with infusion routes allocated in a crossover design. Within main-plot periods, each of
3 subplot periods consisted of 4-d infusions separated with 4-d rest periods. Subplot
treatments were infusion of 1, 3, and 6 g L-carnitine daily. Doses were increased within
a period to minimize carryover. Treatments were delivered in two 10-h infusions daily.
Blood was collected before the start of infusions and on day 4 of each infusion to obtain
baseline and treatment carnitine concentrations. There was a dose × route interaction
(P < 0.05) and route effect (P < 0.01) for increases in plasma carnitine above baseline,
with increases above baseline being greater across all dose levels when infused abomasally compared to ruminally. Results demonstrated superior bioavailability of carnitine
when ruminal exposure was physically bypassed.
Key words: L-carnitine, bioavailability, dairy cow

Introduction

Fatty liver is a metabolic disease that commonly affects postpartum dairy cows. In
response to negative energy balance that typically occurs in early lactation when feed intake is insufficient to meet the high energy demand of lactation, fatty acids are released
from adipose tissue stores as an energy source. However, this lipid mobilization can deliver fatty acids to the liver at a rate that exceeds the organ’s oxidative capacity, resulting
in accumulation of liver lipids which is associated with decreased metabolic function.
L-carnitine plays an essential role in the transport of long chain fatty acids from the
cytosol into the mitochondria of hepatocytes. Increased transport of these fatty acids
can potentially stimulate hepatic long chain fatty acid oxidation, thereby limiting lipid
accumulation.
It has been clearly demonstrated that carnitine can be degraded by ruminal microbes,
but the extent of ruminal degradation is unknown. Abomasal and ruminal infusions of
carnitine have previously been equally effective at increasing plasma carnitine concentrations, suggesting some carnitine might escape ruminal degradation and be available
1
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for intestinal absorption. It has been suggested that degradation rate may be dependent
on diet composition and the length of time animals are fed supplemental carnitine, as
ruminal microbes seem to adapt to carnitine supplementation by increasing degradation rate. Previous studies have assumed up to 80% of supplemental carnitine is ruminally degraded in lactating dairy cows. The objective of this study was to evaluate the
relative bioavailability of carnitine when administered at different sites in the rumen
gastrointestinal tract at varying rates.

Experimental Procedures

Four Holstein heifers previously fitted with ruminal cannulas were used in a split-plot
design to assess the relative bioavailability of ruminally or abomasally administered Lcarnitine. However, one heifer was removed just prior to the end of the first treatment
period due to an intestinal blockage requiring surgery. A second heifer was removed due
to an infection during phase 2 of period 2, and the first heifer removed from the study
replaced her at that time. The study was therefore an incomplete design. Heifers were
housed in a tie-stall facility and fed a dairy ration once daily. The diet met estimated
requirements for all nutrients and was supplemented with niacin (7.8 g/day niacin in
the form of 12 g/day Niashure, Balchem Corp., New Hampton, NY).
The study was conducted in 2 periods, both preceded by 2 weeks without treatment to
obtain baseline samples and for washout between periods. Each period had 3 phases,
each consisting of 4 days of infusions at a different dose of carnitine, with 4 days between phases. The treatments were 1) ruminal infusion of carnitine at 1, 3, and 6 g
carnitine/day and 2) abomasal infusion of 1, 3, and 6 g carnitine/day. Each carnitine
treatment was dissolved in water and also included 6 g/day of larch arabinogalactan,
and total volume infused was 4 L/day across treatments. The dosage used in each phase
escalated, with phase 1 at 1 g/day, phase 2 at 3 g/day, and phase 3 at 6 g/day. The site
of infusion was randomized; 2 heifers received ruminal infusions in period 1, followed
by abomasal infusions in period 2, and the other heifer was treated in the opposite
sequence. Daily infusions (throughout each 4-day infusion) were split into 2 equal
aliquots, each infused during 10-hour infusion periods, allowing 2 hours between infusions.
Throughout the study, feed and water intake were recorded daily with the final three
days of each infusion phase used for analysis. Total mixed ration samples were collected
every two weeks and composited for nutrient analysis by Dairy One Forage Laboratory
(Ithaca, NY; Table 1). Health was monitored daily.
Prior to the start of infusions and at 1.5 hours after initiation of the first daily infusion
on day 4 of each phase, blood samples (coccygeal vein) were collected to obtain baseline
and treatment carnitine concentrations. Concentrations of total carnitine in plasma
were determined by an enzymatic radioisotope method.
Statistical analysis was performed using JMP (version 12, SAS Institute, Cary, NC).
Dependent variables (feed intake, water intake, and change in plasma carnitine concentration) were analyzed to determine the fixed effects of route of administration, dose
of carnitine, and their interaction along with the random effects of heifer and phase
within period. Contrast statements were used to statistically test linear regression coefKansas State University Agricultural Experiment Station and Cooperative Extension Service
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ficients with increasing doses for ruminal vs. abomasal infusions, and least square means
were regressed against dose for the 2 infusion routes to assess relative bioavailability.
Significance was declared at P < 0.05 and tendencies were declared at 0.05 ≤ P ≤ 0.10.

Results and Discussion

Water intake was not affected by carnitine infusion across dose or route (all P > 0.40;
Table 2). Although not affected by infusion route (P = 0.13), dry matter intake (DMI)
did tend to increase quadratically with carnitine dose (P = 0.07), being highest for
the 3 g/day carnitine. The tendency for a DMI effect is likely the result of our small
sample size and was largely driven by data from one heifer. Previous studies have not
documented DMI responses when carnitine was infused abomasally or ruminally up
to 12 g/d. When carnitine was abomasally infused at a high rate (100 g/d), DMI was
decreased during the first two weeks of lactation.
Plasma carnitine concentrations are reported as the difference between baseline and
treatment concentrations in Table 2. A dose × route interaction was observed (P =
0.045), which can largely be attributed to the linear increase in plasma carnitine concentrations with increased dose for abomasal infusion, without a significant effect for
ruminal infusions. A route response was observed (P = 0.005) with carnitine being
more bioavailable across all dose levels when infused abomasally compared to ruminally.
Interestingly, increases in plasma carnitine concentrations in response to ruminal infusion appeared to plateau at 3 g/d; this could be impacted by the sequence of treatments,
given that adaptation of ruminal microbes may enhance carnitine degradation after
a longer period of exposure. It is also possible that L-carnitine transport from the gut
reaches an upper limit at these doses. To further characterize the relative bioavailability of carnitine via these 2 routes of administration, a dose-response analysis was conducted (Figure 1). This assessment suggests that the relative bioavailability of carnitine
is greater when supplied to the abomasum vs. the rumen. It should be noted that this
assumes that increases in plasma concentration are directly related to the amount of
carnitine absorbed.

Conclusion

Carnitine is likely degraded in the rumen, and although the extent of degradation
remains unknown, our findings clearly indicate abomasal administration of carnitine
results in superior bioavailability. Dietary supplementation with rumen encapsulation
may be most effective to maximize carnitine delivery and absorption in the small intestine.
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Table 1. Ingredient and nutritional composition of the basal diet
Item
Ingredient, % of dry matter
Alfalfa hay
Grass hay
Corn silage
Wet corn gluten feed1
Cotton seed
Fine rolled corn
Micronutrient premix2
Nutrient, % of dry matter (unless otherwise specified)
Dry matter, % as-fed
Crude protein
Acid detergent fiber
Neutral detergent fiber
Lignin
Non-fiber carbohydrate
Starch
Crude fat
Net energy for lactation,3 Mcal/lb

Value
21.0
1.7
16.1
25.7
4.4
20.4
10.7

53.5
17.9
24.75
43.8
4.55
26.75
17.9
4.75
0.73

Sweet Bran (Cargill Inc., Blair, NE).
Premix consisted of 58.8% expeller soybean meal (SoyBest, Grain States Soya, West Point, NE), 11.8% limestone,
1.47% stock salt, 1.47% trace mineral salt, 1.47% potassium chloride, 10.3% sodium bicarbonate, 2.35% magnesium oxide. 0.23% 4-Plex (Zinpro Corp., Eden Prairie, MN), 0.12% Zinpro 100 (Zinpro Corp.), 0.25% selenium
premix (0.06%), 0.15% vitamin A premix (30 kIU/g), 0.04% vitamin D premix (30 kIU/g), 1.47% vitamin E
premix (48 kIU/g), 0.01% ethylenediamine dihydriodide premix, 0.06% Rumensin 90 (Elanco Animal Health,
Greenfield, IN), 1.84% XP Yeast (Diamond V, Cedar Rapids, IA), 0.92% Biotin 100 (ADM Alliance Nutrition,
Quincy, IL), and 7.35% Ca salts of long-chain fatty acids (Megalac R, Arm & Hammer Animal Nutrition, Princeton, NJ).
1
2

Table 2: Effect of carnitine infusion on intake performance and plasma carnitine concentration
Ruminal infusion (/day)
Abomasal infusion (/day)
Item
DMI, kg/d
Water intake, L/d
Plasma,2 µM

1g
18.01
7.71
-0.57

3g
18.76
8.04
12.33

6g
18.87
8.60
9.04

1g
16.84
8.27
4.54

3g
19.01
9.24
20.47

6g
17.43
7.88
35.90

pSEM1
0.97
0.69
4.82

Dose
0.07
0.66
0.099

Reported SEM is pooled across route and dose levels.
Plasma concentrations reported are the difference between baseline and treatment concentrations.

1
2
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P - value
Route
0.13
0.58
< 0.01

Dose ×
route
0.35
0.41
0.045
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Figure 1. Marginal plasma carnitine responses to carnitine infusion differ by infusion
route. Differences in plasma carnitine concentrations (post minus pre-infusion concentrations) are plotted against infusion amount. The slopes differ between infusion routes
(P = 0.02), reflecting greater apparent bioavailability for abomasally-delivered carnitine
compared to ruminal infusion.
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